A Randomized Controlled Trial of ProstAtak as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer
Phase of Trial: Phase III
Latest Information Update: 01 Jul 2017
At a glance
- Drugs Aglatimagene besadenovec (Primary) ; Valaciclovir
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms PrTK03
- Sponsors Advantagene
- 10 Jun 2017 Biomarkers information updated
- 17 Apr 2017 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2020.
- 12 Sep 2016 According to an Advantagene media release, this study will be conducted under a Special Protocol Assessment agreement with the U.S. Food & Drug Administration.